Work

1085O Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM)

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.2219

Authors: E. Burton, V. Honaker, D. Milton, I.C. Glitza, R. Amaria, S. Patel, A. Diab, M. Wong, J. Mcquade, C. Chung, J.S. Wefel, J. Li, M. Davies, H.A. Tawbi

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, American Society of Clinical Oncology, Celgene, Les Laboratories Pierre Fabre

OpenAlex ID: W4387811039

FWCI: 0.365

Cites: 1

Cited by: 3

Related to: 10